Eledon Pharmaceuticals, Inc. ELDN 深 沪
等待开盘 08-28 09:30:00 美东时间
3.32
-0.030
-0.90%
华盛通- 最 高3.42
- 今 开3.36
- 成交量 97.12万股
- 最 低 3.245
- 昨 收 3.35
- 总市值 2.70亿
- 52周最高 4.60
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 1.35
- 委 比 -79.40%
- 总股本 8126.12万
- 历史最高 154.98
- 量 比 1.14
- 振 幅 5.22%
- 历史最低 1.07
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from the same period last year.
08-14 04:30
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Zurich-based NewcelX Ltd. announced a private placement of 347,134 common shares at a 20% premium to its July 30 closing price, with warrants exercisable at 132% of that price. The offering, including participation from existing shareholders, is expected to close on Aug. 14. Proceeds will support the advancement of NCEL-101, the company's lead type 1 diabetes program, following a successful FDA Pre-IND meeting. CEO Ronen Twito highlighted investo...
07-31 13:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-21 19:53
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significa...
07-01 21:33
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote
The latest update is out from Eledon Pharmaceuticals ( ($ELDN) ). At its Annual...
06-23 06:47
Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated pat...
06-22 19:15
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW trial for tegoprubart in kidney transplant patients. Results showed sustained kidney function benefits, with a statistically significant 12 mL/min/1.73 m² higher eGFR at 18 months vs. tacrolimus. No biopsy-proven acute rejection (BPAR) events were observed after six months in tegoprubart-treated patients, compared to seven BPAR events in the tacrolimus arm. Patient-report...
06-22 11:00
Eledon Pharmaceuticals To Present Updated Data From Investigator-Initiated Study At American Diabetes Association 86th Scientific Sessions
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented
06-05 04:33
Eledon Pharma To Highlight New Clinical Data From Tegoprubart Program In Patients Undergoing Kidney Transplantation In Oral And Poster Presentation At ATC 2026
Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster
05-21 04:16
